A California judge ruled in favor of an older Black and disabled worker to continue a lawsuit alleging that Workday's AI-powered screening tools discriminated against minority job seekers. The class ...
Today, the Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis ...
The initial lawsuit was filed in 2023 by Derek Mobley, who claimed Workday's algorithm discriminated against him because he's ...
Abstract: Robust multiobjective optimization problems (RMOPs) widely exist in real-world applications, which introduce a variety of uncertainty in optimization models. While some evolutionary ...
BmoreArt’s Picks presents the best weekly art openings, events, and performances happening in Baltimore and surrounding areas ...
MiniMed , a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMedtm 780G system integrated with the Instinct sensor and the MiniMed Gotm system ...
Abstract: Deep learning (DL), a branch of machine learning (ML), is the core technology in today’s technological advancements and innovations. Deep learning-based approaches are the state-of-the-art ...
Trump signed a preliminary agreement with Iran yesterday to end the war and open the Strait of Hormuz. And, the president's ...
13d
Judge signals AI recruitment tool vendors like Workday may not escape liability for discrimination
By allowing lawsuits to proceed, a federal judge may be opening the door to broader liability for AI tool vendors, and ...
AI, refers to the simulation of human intelligence by computers and other machines. Increasingly, there are AI applications that can problem-solve, understand and mimic human language, identify ...
AstraZeneca is moving its oral GLP-1 candidate into late-stage testing after seeing its midstage results. (Li Ziheng/Xinhua via Getty Images) When looking out across the competitive GLP-1 landscape, ...
The American Diabetes Association (ADA) recently released their 2025 Standards of Care, which – for the first time – includes recommendations for CGM use in type 2 diabetes, the use of GLP-1 drugs for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results